跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
姜 紹青
助理教授
藥學系
電話
(02)2826-7000#65688
電子郵件
scchiang316
nycu.edu
tw
h-index
h10-index
h5-index
50
引文
4
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
38
引文
4
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
34
引文
3
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2004
2025
每年研究成果
概覽
指紋
網路
研究成果
(24)
類似的個人檔案
(4)
指紋
查看啟用 Shao-Chin Chiang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Taiwan
100%
Granulocyte Colony-stimulating Factor (G-CSF)
67%
Hazardous Drugs
66%
Chemotherapy
50%
Safe Handling
44%
Breast Cancer
44%
Antineoplastic Agents
33%
Patients with Breast Cancer
33%
Febrile Neutropenia
32%
Multidisciplinary Consensus
29%
Chemotherapy-induced Neutropenia
29%
Metastatic Breast Cancer
29%
Consensus Guidelines
29%
Taiwan National Health Insurance
29%
Biosimilar
29%
Primary Prophylaxis
28%
Breast Cancer Patients
26%
Antineoplastic Drugs
25%
Pharmacist
23%
Neutropenic
23%
Risk Model
22%
Closed-system Transfer Device
20%
Women with Breast Cancer
19%
Chemotherapy Administration
19%
Cost-effectiveness
19%
Healthcare Professionals
18%
Taiwanese
18%
Chemotherapy Treatment
17%
Chemotherapy Drugs
16%
Cancer Patients
15%
Best Possible Medication History
14%
PharmaCloud
14%
Prescription Pattern
14%
Pazopanib
14%
Microglial M2 Polarization
14%
National Health System
14%
Matched Cohort Study
14%
Non-Hodgkin Lymphoma
14%
Health Care Costs
14%
Lymphoma Patients
14%
Risk Assessment Tool
14%
Cancer Chemotherapy
14%
Practice Management
14%
Cancer Pharmacotherapy
14%
Handling Practices
14%
Clinical Pharmacy
14%
Drug Handling
14%
Health State Utility
14%
Evidence-based Risk Assessment
14%
Metastatic Renal Cell Carcinoma (mRCC)
14%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
88%
Chemotherapy
85%
Hazardous Drugs
67%
Febrile Neutropenia
53%
Granulocyte Colony Stimulating Factor
52%
Malignant Neoplasm
30%
Metastatic Breast Cancer
29%
Cohort Study
29%
Neutropenia
19%
Nonhodgkin Lymphoma
14%
Kidney Metastasis
14%
Pharmacotherapy
14%
Health Status
14%
Pazopanib
14%
Drug System
14%
Lipopolysaccharide-Induced Neuroinflammation
14%
Ellagic Acid
14%
Acquired Immune Deficiency Syndrome
14%
Human Immunodeficiency Virus Infection
14%
Clinical Pharmacy
14%
Lipopolysaccharide
13%
HIV
11%
Antineoplastic Agent
9%
Sunitinib
8%
Pegfilgrastim
8%
Compounding
8%
Adverse Drug Reaction
6%
Clinical Trial
6%
Nervous System Inflammation
5%
Infection
5%
Nursing and Health Professions
Practice Guideline
76%
Breast Cancer
73%
Hazardous Drugs
48%
Granulocyte Colony Stimulating Factor
39%
Neutropenia
34%
Metastatic Breast Cancer
29%
Febrile Neutropenia
28%
National Health Insurance
20%
Cohort Analysis
20%
Hospital Organization
14%
Medication Therapy Management
14%
Health Status
14%
Health Care Cost
14%
Predictive Value
14%
World Health Organization
11%
Health Care Personnel
11%
Logistic Regression Analysis
9%
Staff Training
9%
Malignant Neoplasm
7%
Protective Equipment
6%
Periodic Medical Examination
6%
Adverse Drug Reaction
6%
Odds Ratio
6%
Visual Analog Scale
6%
Infection
6%
Outpatient
6%
Medication Error
6%
